Recovery of PEX1-gly843Asp peroxisome dysfunction by small-molecule compounds

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 12, 2010, Pages 5569-5574

  Zhang, Rui ^a   Chen, Li ^b   Jiralerspong, Sarn ^c   Snowden, Ann ^c   Steinberg, Steven ^c   Braverman, Nancy ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c KENNEDY KRIEGER INSTITUTE   (United States)

Author keywords

AAA ATPase; Chemical screening; Misfolded protein; Pharmacologic chaperone; Zellweger spectrum

Indexed keywords

ASPARTIC ACID; GLYCINE; GREEN FLUORESCENT PROTEIN; MATRIX PROTEIN;

ARTICLE; CONTROLLED STUDY; CYTOSOL; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; PEROXISOME; PHENOTYPE; PRIORITY JOURNAL; SCREENING; ZELLWEGER SYNDROME;

ADENOSINE TRIPHOSPHATASES; AMINO ACID SUBSTITUTION; BETAINE; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; GENES, REPORTER; GLYCEROL; GREEN FLUORESCENT PROTEINS; HUMANS; MEMBRANE PROTEINS; METHYLAMINES; MUTATION, MISSENSE; PEROXISOMES; PROTEIN FOLDING; RECEPTORS, CYTOPLASMIC AND NUCLEAR; ZELLWEGER SYNDROME;

EID: 77950409779     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0914960107     Document Type: Article

References (39)

1. Collins CS, Gould SJ (1999) Identification of a common PEX1 mutation in Zellweger syndrome. Hum Mutat 14:45-53.
2. Preuss N, et al. (2002) PEX1 mutations in complementation group 1 of Zellweger spectrum patients correlate with severity of disease. Pediatr Res 51:706-714. (Pubitemid 34547333)
3. Walter C, et al. (2001) Disorders of peroxisome biogenesis due to mutations in PEX1: Phenotypes and PEX1 protein levels. Am J Hum Genet 69:35-48. (Pubitemid 32614016)
4. Osumi T, et al. (2000) Temperature sensitivity in peroxisome assembly processes characterizes milder forms of peroxisome biogenesis disorders. Cell Biochem Biophys 32:165-170.
5. Raas-Rothschild A, et al. (2002) A PEX6-defective peroxisomal biogenesis disorder with severe phenotype in an infant, versus mild phenotype resembling Usher syndrome in the affected parents. Am J Hum Genet 70:1062-1068. (Pubitemid 34259327)
6. Imamura A, et al. (2000) Temperature-sensitive mutation of PEX6 in peroxisome biogenesis disorders in complementation group C (CG-C): Comparative study of PEX6 and PEX1. Pediatr Res 48:541-545.
7. Matsumoto N, et al. (2003) Mutations in novel peroxin gene PEX26 that cause peroxisome-biogenesis disorders of complementation group 8 provide a genotype-phenotype correlation. Am J Hum Genet 73:233-246. (Pubitemid 36920988)
8. Hashimoto K, et al. (2005) Molecular mechanism of a temperature-sensitive phenotype in peroxisomal biogenesis disorder. Pediatr Res 58:263-269. (Pubitemid 41099872)
9. Gregersen N, Bolund L, Bross P (2003) Protein misfolding, aggregation, and degradation in diseases. Protein Misfolding and Disease, eds Bross B, Gregersen N (Humana Press, Totowa, NJ), pp 3-17.
10. Maxwell MA, et al. (1999) A common PEX1 frameshift mutation in patients with disorders of peroxisome biogenesis correlates with the severe Zellweger syndrome phenotype. Hum Genet 105:38-44.
11. Platta HW, Debelyy MO, El Magraoui F, Erdmann R (2008) The AAA peroxins Pex1p and Pex6p function as dislocases for the ubiquitinated peroxisomal import receptor Pex5p. Biochem Soc Trans 36:99-104.
12. Geisbrecht BV, Collins CS, Reuber BE, Gould SJ (1998) Disruption of a PEX1-PEX6 interaction is the most common cause of the neurologic disorders Zellweger syndrome, neonatal adrenoleukodystrophy, and infantile Refsum disease. Proc Natl Acad Sci USA 95:8630-8635.
13. Wei H, Kemp S, McGuinness MC, Moser AB, Smith KD (2000) Pharmacological induction of peroxisomes in peroxisome biogenesis disorders. Ann Neurol 47:286-296. (Pubitemid 30141837)
14. Perlmutter DH (2002) Chemical chaperones: A pharmacological strategy for disorders of protein folding and trafficking. Pediatr Res 52:832-836.
15. Kurochkin IV, et al. (2007) Novel peroxisomal protease Tysnd1 processes PTS1- and PTS2-containing enzymes involved in beta-oxidation of fatty acids. EMBO J 26: 835-845.
16. Brandt D, Gimona M, Hillmann M, Haller H, Mischak H (2002) Protein kinase C induces actin reorganization via a Src- and Rho-dependent pathway. J Biol Chem 277: 20903-20910.
17. Platta HW, Grunau S, Rosenkranz K, Girzalsky W, Erdmann R (2005) Functional role of the AAA peroxins in dislocation of the cycling PTS1 receptor back to the cytosol. Nat Cell Biol 7:817-822. (Pubitemid 41079054)
18. Li JW, Vederas JC (2009) Drug discovery and natural products: End of an era or an endless frontier? Science 325:161-165.
19. Hanson PI, Whiteheart SW (2005) AAA+ proteins: Have engine, will work. Nat Rev Mol Cell Biol 6:519-529.
20. Tamura S, Yasutake S, Matsumoto N, Fujiki Y (2006) Dynamic and functional assembly of the AAA peroxins, Pex1p and Pex6p, and their membrane receptor Pex26p. J Biol Chem 281:27693-27704. (Pubitemid 44414483)
21. Benjamin ER, et al. (2009) The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines. J Inherit Metab Dis 32:424-440.
22. Robben JH, Sze M, Knoers NV, Deen PM (2007) Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: Relevance to therapy of nephrogenic diabetes insipidus. Am J Physiol Renal Physiol 292:F253-F260. (Pubitemid 46105265)
23. Aszalos A (2008) Role of ATP-binding cassette (ABC) transporters in interactions between natural products and drugs. Curr Drug Metab 9:1010-1018.
24. Marini H, et al. (2007) Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: A randomized trial. Ann Intern Med 146: 839-847.
25. Lin TS, et al. (2009) Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 27:6012-6018.
26. Katayama K, et al. (2007) Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: Transporter specificity and structure-activity relationship. Cancer Chemother Pharmacol 60:789-797. (Pubitemid 47389385)
27. Trompier D, et al. (2003) Multiple flavonoid-binding sites within multidrug resistance protein MRP1. Cell Mol Life Sci 60:2164-2177. (Pubitemid 37357424)
28. Nissler L, Gebhardt R, Berger S (2004) Flavonoid binding to a multi-drug-resistance transporter protein: An STD-NMR study. Anal Bioanal Chem 379:1045-1049.
29. Teillet F, Boumendjel A, Boutonnat J, Ronot X (2008) Flavonoids as RTK inhibitors and potential anticancer agents. Med Res Rev 28:715-745.
30. Lu H, Chang DJ, Baratte B, Meijer L, Schulze-Gahmen U (2005) Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin. J Med Chem 48:737-743. (Pubitemid 40209095)
31. Morita M, et al. (2008) Baicalein 5,6,7-trimethyl ether activates peroxisomal but not mitochondrial fatty acid beta-oxidation. J Inherit Metab Dis 31:442-449.
32. Toullec D, et al. (1991) The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem 266:15771-15781.
33. Blanquart C, et al. (2004) The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor alpha. Mol Endocrinol 18:1906-1918. (Pubitemid 39006498)
34. Meyer MC, Kell PJ, Creer MH, McHowat J (2005) Calcium-independent phospholipase A2 is regulated by a novel protein kinase C in human coronary artery endothelial cells. Am J Physiol Cell Physiol 288:C475-C482.
35. Hubbard WC, et al. (2009) Newborn screening for X-linked adrenoleukodystrophy (XALD): Validation of a combined liquid chromatography-tandem mass spectrometric (LC-MS/MS) method. Mol Genet Metab 97:212-220.
36. Counter CM, et al. (1998) Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene 16: 1217-1222. (Pubitemid 28127521)
37. Hopert A, Uphoff CC, Wirth M, Hauser H, Drexler HG (1993) Mycoplasma detection by PCR analysis. In Vitro Cell Dev Biol Anim 29A:819-821.
38. Braverman N, et al. (2000) PEX7 gene structure, alternative transcripts, and evidence for a founder haplotype for the frequent RCDP allele, L292ter. Genomics 63:181-192. (Pubitemid 30131944)
39. Roscher A, et al. (1985) The cerebrohepatorenal (Zellweger) syndrome: An improved method for the biochemical diagnosis and its potential value for prenatal detection. Pediatr Res 19:930-933.